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Infertility affects 1 in 8 couples, but over the 17 years of
the study Udell et al. (1) reported in this edition of the
Journal, the proportion of pregnancies conceived after
fertility treatment rose from 1 in 400 to 1 in 80. These
data support the idea that although the prevalence of
infertility is stable over time, the number of couples with
infertility would have been substantially higher if in vitro
fertilization and other types of assisted conception had not
been introduced. Thanks to these techniques, many
couples are successfully treated and happily raise a family.
See page 1704
We know pregnancy is a “stress test” for later cardiovascular
and metabolic disease. Indeed, complications arising during
pregnancy may actually be the ﬁrst presentation of
a subclinical disease. For instance, in the case of gestational
diabetes mellitus, women diagnosed with gestational dia-
betes mellitus have a 50% to 60% chance of diabetes
developing in the next 10 to 15 years. Further, the occur-
rence of pre-eclampsia is a strong predictor for hypertension
and subsequent cardiovascular events, perhaps by unmasking
subclinical endothelial dysfunction.
The study reported by Udell et al. (1), in this issue of the
Journal, examines whether fertility treatment, either by
inducing extremely high levels of sex steroids or by another
mechanism, results in an increase in later cardiovascular and
metabolic disease. Does the therapy inﬂuence the occurrence
of thromboembolic events? Personally, I have seen a woman
treated for infertility who subsequently had major pulmonary
emboli and pulmonary hypertension. She was severely
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contents of this paper to disclose.population who seek fertility treatment, we know there is
an excess of women with polycystic ovarian disease and other
cardiovascular risk factors, as also shown by the current
study. These women are at greater risk of gestational dia-
betes mellitus and pre-eclampsia, both associated with later
metabolic and cardiovascular disease, as also found in the
current study. It has been proven that lifestyle changes,
including diet, exercise, and behavioral modiﬁcation, appear
to improve the metabolic and reproductive abnormalities
of overweight and obese patients with polycystic ovary
syndrome (2). However, the important question posed by
this study is, does fertility treatment increase the risk of
cardiovascular events? If it were to do so, then the next
question is, is this an effect of the treatment or is the
treatment and subsequent pregnancy revealing an already-
existing tendency to a disease. Either mechanism would
result in an increase in disease diagnosis within a deﬁned
period, the former by a direct adverse effect and the latter by
hastening the time of diagnosis of a subclinical condition.
It is important to study the effects of fertility treatment on
cardiovascular outcomes in women. However, although the
question is of great clinical relevance, it is not easy to design
a study to elucidate this question. A randomized controlled
trial is not an option as infertility itself is a confounding
factor, and also a case-control study is not possible. A large
population-based study seems the best way of approaching
this problem. It is, however, difﬁcult to retrieve reliable data
in a large cohort of patients. Therefore, Udell et al. (1) should
be congratulated on completing a well-designed and well-
performed study. They have investigated a population-based
cohort of 1,186,753 women who delivered between 1993
and 2010, of whom 6,979 gave birth after fertility therapy.
Interestingly, after 10 years of follow-up, the researchers
found that the rate of the primary outcome, namely,
a composite of death or hospitalization for a major adverse
cardiovascular event including nonfatal coronary ischemia,
stroke, transient ischemic attack, thromboembolism, or heart
failure, was lower among women who had received fertility
treatment. In terms of the individual components, mortality
(adjusted hazard ratio: 0.50, 95% conﬁdence interval: 0.31 to
0.80, p ¼ 0.004) and thromboembolic events (adjusted
hazard ratio: 0.45, 95% conﬁdence interval: 0.21 to 0.94,
p ¼ 0.03) were signiﬁcantly reduced, but crude rates of
coronary ischemic events, heart failure, and cerebrovascular
events were higher, yet each association was not signiﬁcant
after multivariable adjustment. Similarly, after excluding
women who had evidence of cardiovascular disease, hyper-
tension, diabetes (including gestational diabetes), or hyper-
lipidemia at baseline, the development of risk factors
occurred more frequently among women after fertility
therapy than among controls. However, again after adjust-
ment with the multivariate analysis, these changes were
reversed. These data show that not only was fertility treat-
ment associated with a reduction in death and thrombo-
embolic disease, but it also seemed to protect against the
development of risk factors for cardiovascular disease.
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1714The investigators suggest 3 possible explanations for
the beneﬁcial effect of successful fertility treatment. First,
women who have had successful fertility treatment opt for
a healthier lifestyle than women who conceived without
fertility treatment; second, that the treatment has some
beneﬁcial effect; and third, that women who have unhealthy
lifestyles do not choose to have fertility treatment. Given
that the population receiving fertility treatment at baseline
had more cardiovascular risk factors, then it would seem
unlikely that they were a particularly healthy group. Ferti-
lity treatment is unlikely to have some intrinsic health-
promoting effect, suggesting that the last option, the
adoption of a healthy lifestyle, is the most likely. However,
this would be very difﬁcult to prove.
Of course, longer duration of follow-up is warranted and
the discussion is not yet closed, but the ﬁndings in this study
are reassuring for women who need fertility treatment.
However, some methodological issues of the study need
attention. Especially, the large differences found at baseline,
such as a difference in age, make reliable comparison difﬁ-
cult. Udell et al. (1) have tried to correct this, but that could
not be done for all parameters. In addition, in this study, no
information is obtained about unsuccessful fertility treat-
ment, especially that these patients may have received higher
cumulative doses of hormones with consequently more effect
on cardiovascular outcome.The current data are reassuring as they suggest that
fertility treatment does not itself increase the risk of
cardiovascular events or risk factors and may actually have
a direct or indirect beneﬁcial effect, but overall, we should
remember that the population needing fertility treatment is
actually at increased risk of cardiovascular and metabolic
disease. Further, these data can only be applied to women
who conceived and had a live birth. The outcome for women
whose treatment is unsuccessful may be very different and
should be investigated.
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